Render Target: STATIC
Render Timestamp: 2025-01-21T21:30:36.475Z
Commit: da7e4f2f0d1aed1f1f8e20e4e2ecab8f33cbd595
XML generation date: 2024-10-29 22:01:06.219
Product last modified at: 2025-01-01T09:04:39.951Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CrkL (D4G7G) Rabbit mAb #38710

Filter:
  • WB
  • IP
Western Blotting Image 1: CrkL (D4G7G) Rabbit mAb
Western blot analysis of extracts from various cell lines using CrkL (D4G7G) Rabbit mAb (upper) and β-Actin (D6A8) Rabbit mAb #8457 (lower).

To Purchase # 38710

Cat. #

Size

38710T
20 µl
38710S
100 µl

Supporting Data

REACTIVITY H
SENSITIVITY Endogenous
MW (kDa) 39
Source/Isotype Rabbit IgG
Application Key:
  • WB-Western Blotting 
  • IP-Immunoprecipitation 
Species Cross-Reactivity Key:
  • H-Human 

Product Information

Product Usage Information

Application Dilution
Western Blotting 1:1000
Immunoprecipitation 1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

For a carrier free (BSA and azide free) version of this product see product #71569.

Protocol

Specificity / Sensitivity

CrkL (D4G7G) Rabbit mAb recognizes endogenous levels of total human CrkL protein.

Species Reactivity:

Human

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Thr120 of human CrkL protein.

Background

CrkL, a 39 kDa adaptor protein, has a key regulatory role in hematopoietic cells. CrkL has one SH2 and two SH3 domains, with 60% homology to CrkII (1). The amino-terminal SH3 domain of CrkL binds proteins, such as C3G, SOS, PI3K, c-Abl, and BCR/Abl. The SH2 domain of CrkL can bind to tyrosine-phosphorylated proteins, such as Cbl, HEF1, CAS, and paxillin (2,3). CrkL is involved in various signaling cascades initiated by different cytokines and growth factors. The biological outcomes of the Crk-activated signal transduction include the modulation of cell adhesion, cell migration, and immune cell responses (4). CrkL is a prominent substrate of the BCR/Abl oncoprotein in chronic myelogenous leukemia and binds to both BCR/Abl and c-Abl (5). CrkL is prominently and constitutively tyrosine phosphorylated in CML neutrophils and is not phosphorylated in normal neutrophils. Moreover, stimulation of normal neutrophils with cytokines and agonists does not induce tyrosine phosphorylation of this protein (6), indicating that it may be a useful target for therapeutic intervention or as a disease marker. Tyr207 in CrkL is the BCR/Abl phosphorylation site (7).

Pathways

Explore pathways related to this product.


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our Trademark Information page.